- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Difficulties in the clinical diagnosis of corticobasal degeneration
-
- Hayashi Yuichi
- Department of Neurology, Gifu University Graduate School of Medicine
-
- Shimohata Takayoshi
- Department of Neurology, Gifu University Graduate School of Medicine
Bibliographic Information
- Other Title
-
- 大脳皮質基底核変性症:臨床診断をめぐる問題点
Search this article
Description
<p>The clinical diagnosis of corticobasal degeneration (CBD) is challenged by the existence of various phenotypes of CBD except corticobasal syndrome (CBS), CBD mimics, and immune–related CBS. Previously, 37% of the pathologically–verified CBD cases only had CBS, while the others presented progressive supranuclear palsy (PSP) syndrome, frontotemporal dementia (FTD), Alzheimer disease (AD)–like dementia or aphasia. Moreover, another report showed that 46% of CBS or CBD cases diagnosed by the clinical criteria were CBD mimics, which includes PSP, AD, FTD, globular glial tauopathy, prion disease, and other tauopathies. Recently, an anti–IgLON5 antibody related disease mimicking CBS was reported. The patient's symptoms were consistent for probable CBS ; however, some clinical and radiological findings were partially improved by immunotherapy. Therefore, the clinicians should be aware that such an anti–IgLON5 antibody related disease exists as a differentiated CBS, and more accurate clinical diagnostic criteria for CBD should be established.</p>
Journal
-
- Neurological Therapeutics
-
Neurological Therapeutics 39 (4), 465-467, 2022
Japanese Society of Neurological Therapeutics
- Tweet
Details 詳細情報について
-
- CRID
- 1390294562487929856
-
- ISSN
- 21897824
- 09168443
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed